Abstract
Background Ambitious population-based screening programs for latent and active tuberculosis (TB) were implemented in the Republic of the Marshall Islands (RMI) in 2017 and 2018.
Methods We used a transmission dynamic model of TB informed by local data to capture the historical dynamics of the RMI epidemic. We then used the model to project the future epidemic trajectory following the active screening interventions, as well as considering a counterfactual scenario with no intervention. We also simulated future scenarios including periodic interventions similar to those previously implemented, to assess their ability to reach the End TB Strategy targets and TB pre-elimination in RMI.
Findings The screening activities conducted in 2017 and 2018 were estimated to have reduced TB incidence and mortality by more than one third in 2020, and are predicted to achieve the End TB Strategy milestone of 50% incidence reduction by 2025 compared to 2015. Screening interventions had a considerably greater impact when latent TB screening and treatment was included, compared to active case finding alone. Such combined programs implemented at the national level could achieve TB pre-elimination around 2035 if repeated every two years, and around 2045 if repeated every five years.
Interpretation Our model suggests that it would be possible to achieve TB pre-elimination by 2035 in RMI through periodic repetition of the same interventions as those already implemented in the country. It also highlights the importance of including latent infection testing in active screening activities.
Funding Australian National Health and Medical Research Council and World Health Organization.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was funded by the Australian National Health and Medical Research Council (Project Grant APP1144570 and Fellowship Grant APP1142638) and the Western Pacific Regional Office of the World Health Organization.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
NA
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data and code used to implement the study are available on a Github repository.
https://github.com/monash-emu/AuTuMN/tree/master/apps/tuberculosis/regions/marshall_islands
